O'Day, Roderick FJ;
Roelofs, Kelsey A;
Negretti, Guy S;
Hay, Gordon;
Arora, Amit K;
Stoker, Ian;
Damato, Bertil E;
... Cohen, Victoria ML; + view all
(2022)
Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma.
Eye
10.1038/s41433-022-01944-4.
(In press).
Preview |
Text
VAP_final_2 mss.pdf - Accepted Version Download (256kB) | Preview |
Abstract
BACKGROUND: To assess the long-term visual outcomes in patients with posteriorly located choroidal melanoma treated with ruthenium plaque brachytherapy between January 2013 and December 2015. METHODS: A retrospective review was conducted on consecutive patients treated with ruthenium plaque brachytherapy for post-equatorial choroidal melanoma with available Snellen visual acuity before and after treatment, and the development and treatment of radiation complications. RESULTS: There were 219 patients with posterior choroidal melanoma treated with ruthenium plaque brachytherapy. Median follow up was 56.5 months, range 12-81 months. Final visual acuity was ≥6/12 in 97 (44.3%) patients, 6/12 to 6/60 in 57 (26.0%), <6/60 in 55 (25.1%) and 10 (4.6%) eyes were enucleated. Radiation maculopathy was the most common radiation complication encountered, occurring in 53 (24.2%) patients. Of these, final visual acuity was 6/12 in 10 patients (18.9%), 6/12 to 6/60 in 26 (49.1%), <6/60 in 16 (30.2%) and 1 eye (1.9%) was enucleated. Twenty-five (47%) with radiation maculopathy were treated with intravitreal anti-angiogenic therapy, 27 (51%) were monitored and one (2%) was treated with scatter photocoagulation. Eyes treated with intravitreal anti-angiogenic therapy had better final vision than those observed or treated with retinal laser (chi-square, p = 0.04). On multivariate analysis, close proximity to the optic nerve and fovea, and large or notched plaque type was associated with final vision worse than 6/12. CONCLUSION: Most patients treated with ruthenium plaque brachytherapy for posterior choroidal melanoma retain 6/60 vision, with almost half retaining 6/12 vision at long term follow up.
| Type: | Article |
|---|---|
| Title: | Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41433-022-01944-4 |
| Publisher version: | https://doi.org/10.1038/s41433-022-01944-4 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Ophthalmology, COMS RANDOMIZED TRIAL, LOCAL TUMOR-CONTROL, UVEAL MELANOMA, RU-106 BRACHYTHERAPY, DOSE-RATE, RADIOTHERAPY, RADIATION, ACUITY, I-125, COMPLICATIONS |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10149294 |
Archive Staff Only
 |
View Item |
